![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Virology analyses of simeprevir in Phase 2b and 3 studies
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Oliver Lenz,1 Thierry Verbinnen,1 Bart Fevery,1 Lotke Tambuyzer,1 Leen Vijgen,1 Monika Peeters,1 Annemie Buelens,1 Maria Beumont-Mauviel,1
Gaston Picchio,2 Sandra De Meyer1
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Research & Development, LLC, Titusville, NJ, USA
![EASL1.gif](../images/041814/041714-3/EASL1.gif)
![EASL2.gif](../images/041814/041714-3/EASL2.gif)
![EASL3.gif](../images/041814/041714-3/EASL3.gif)
![EASL4.gif](../images/041814/041714-3/EASL4.gif)
![EASL5.gif](../images/041814/041714-3/EASL5.gif)
![EASL6.gif](../images/041814/041714-3/EASL6.gif)
![EASL7.gif](../images/041814/041714-3/EASL7.gif)
![EASL8.gif](../images/041814/041714-3/EASL8.gif)
![EASL9.gif](../images/041814/041714-3/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|